The responses of CK19+ and CK19− HCC to different chemotherapeutic drugs are quite different, and CK19+ HCC has been confirmed to be resistant to chemotherapy, such as 5-fluorouracil and doxorubicin [5–7]. Here, KRT19 is linked to hepatocellular carcinoma.